Baylor College of Medicine: Promising Approach To Mitigate Complications Of Leukemia Treatment
September 28, 2022
September 28, 2022
HOUSTON, Texas, Sept. 28 (TNSjou) -- The Baylor College of Medicine issued the following news:
Researchers at Baylor College of Medicine and collaborating institutions have engineered immune cells to control two major life-threatening complications, namely graft-vs-host disease (GvHD) and cancer relapse, which typically emerge after treating leukemia with allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Published in the journal Blood, the findings in anim . . .
Researchers at Baylor College of Medicine and collaborating institutions have engineered immune cells to control two major life-threatening complications, namely graft-vs-host disease (GvHD) and cancer relapse, which typically emerge after treating leukemia with allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Published in the journal Blood, the findings in anim . . .